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Background: Major depressive disorder (MDD) places a significant disease burden on individuals as well as on
societies. Several web-based interventions for MDD have shown to be effective in reducing depressive symptoms.
However, it is not known whether web-based interventions, when used as adjunctive treatment tools to regular
psychotherapy, have an additional effect compared to regular psychotherapy for depression.
Methods/design: This study is a currently recruiting pragmatic randomized controlled trial (RCT) that compares
regular psychotherapy plus a web-based depression program (“deprexis”) with a control condition exclusively
receiving regular psychotherapy. Adults with a depressive disorder (N = 800) will be recruited in routine secondary
care from therapists over the course of their initial sessions and will then be randomized within therapists to one of
the two conditions. The primary outcome is depressive symptoms measured with the Beck Depression Inventory
(BDI-II) at three months post randomization. Secondary outcomes include changes on various indicators such as
anxiety, somatic symptoms and quality of life. All outcomes are again assessed at the secondary endpoint six
months post randomization. In addition, the working alliance and feasibility/acceptability of the treatment condition
will be explored.
Discussion: This is the first randomized controlled trial to examine the feasibility/acceptability and the effectiveness
of a combination of traditional face-to-face psychotherapy and web-based depression program compared to
regular psychotherapeutic treatment in depressed outpatients in routine care.
Trial registration: ISRCTN20165665.
Keywords: Depression, Internet-based treatment, Adjunctive treatment tool, Randomized controlled trial (RCT)Background
Major depressive disorders (MDD) are among the leading
causes of worldwide disability [1]. Several meta-analysis
have shown that web-based self-help interventions can
contribute to depressive symptom reduction and there is
considerable support for the use of the Internet for deliv-
ering evidence-based psychotherapy for depression [2-7].
However, several studies suggest that web-based self-help
interventions without support seem to result in more* Correspondence: tobias.krieger@psy.unibe.ch
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unless otherwise stated.modest outcomes and considerably higher dropout rates
than treatments including regular web-based support
from therapists or technically qualified persons [6,8-10].
There is growing knowledge about the effects of web-
based interventions. However, research on combining
web-based technologies with traditional face-to-face ther-
apy, i.e., blended treatments, is sparse. Importantly, the
term blended treatment includes any possible combin-
ation of regular face-to-face treatments and web-based
interventions. For instance, treatment components of a
web-delivered intervention may be integrated intensively
and used during the face-to-face treatment, or, as in the
current study, may rather be used as an adjunctiveLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Krieger et al. BMC Psychiatry 2014, 14:285 Page 2 of 8
http://www.biomedcentral.com/1471-244X/14/285intervention. Since research on blended treatments is
scarce, it remains to a large extent an open question if and
how web-based interventions can be combined meaning-
fully with traditional forms of psychotherapy and whether
this may have an incremental effect [11].
So far, only a few studies have investigated combinations
of regular face-to-face therapy and web-based adjunctive
tools in mental disorders. For example, there are promising
results regarding symptomatology and acceptability for
(palmtop-) computer-assisted psychotherapies in different
anxiety disorders [12-14]. Furthermore, in a study in which
77 individuals seeking treatment for substance dependence
were randomly assigned to regular face-to-face psychother-
apy or regular face-to-face psychotherapy with biweekly ac-
cess to a computer-based training in cognitive-behavioral
therapy (CBT), participants in the blended condition sub-
mitted significantly more drug-negative urine specimens
and tended to have longer continuous periods of abstin-
ence during treatment [15]. Moreover, a 6-month follow-
up showed significantly better durability of effects of the
combined treatment over regular treatment for both
self-report and urinalysis data [16]. These results were
replicated in a larger randomized clinical trial in a more
homogeneous clinical population, i.e., cocaine-dependent
individuals maintained on methadone [17].
Regarding MDD and combined treatments, research is
very sparse. For example, Wright and colleagues conducted
an open trial of a computer-assisted psychotherapeutic
treatment in a sample consisting predominantly of patients
suffering from depression. Results indicated a high rate of
patient acceptance of this form of treatment, and scores of
symptom severity as well as the mean score on a measure
of cognitive therapy knowledge were significantly improved
[18]. Subsequently, Wright and colleagues [19] conducted
a RCT comparing a conventional face-to-face cognitive
therapy (CT), a wait-list, and computer-assisted cognitive
therapy with reduced therapist contact in patients suffering
from a MDD. Results indicated that the combined con-
dition was more effective than the wait-list condition
and equally effective as conventional CT. These effects
were maintained over a 6-month period. Furthermore,
computer-assisted cognitive therapy showed more robust
effects, relative to being wait-listed, than standard cogni-
tive therapy in reducing measures of cognitive distortion
and in improving knowledge about cognitive therapy.
Recently, Mansson et al. [20] conducted a proof-of-
concept study on the effectiveness of a blended form of
psychotherapy in a mixed anxious-depressed sample.
The adjunctive web-based platform was to be used at
home and in the clinical setting where treatment was pro-
vided. The main part of the platform consisted mainly of
material that would have been presented on paper or ver-
bally in a face-to-face session. Additionally, the platform
comprised some basic components of CBT, such asscheduling sessions, keeping an agenda, and setting goals.
Results indicated that this blended treatment had a posi-
tive effect across anxious and depressive symptom mea-
sures as well as on a quality of life measure in a mixed
sample of 15 patients suffering from MDD and/or anxiety
disorders. Additionally, patients as well as therapists rated
the treatment mostly favorably. Positive patients’ feedback
included, for example: memory support and learning, po-
tential to gain an overview of the treatment process, posi-
tive implications for homework assignments, promotion
of a sense of autonomy and responsibility.
The literature cited above indicates that combining
traditional face-to-face psychotherapy and web-based tools
may be a promising venue. A possible explanation for these
results is highlighted by a recent review, which concludes
that patients’ treatment adherence may be improved
through new technologies [21]. Potential benefits of blend-
ing treatments could for example be a greater reduction of
depressive symptoms or more cost-efficacious treatments
[19]. However, there could also be some serious downsides
of combining conventional face-to-face treatments and
new technologies. For example, a recent randomized con-
trolled study showed that appointment reminder via SMS
did not lead to higher appointment attendance as expected
and, more importantly, that more client dropped out in the
reminder condition compared to the no reminder condi-
tion [22]. Finally, to our knowledge there is no study that
investigates how the blending of treatments affects import-
ant process variables such as the therapeutic alliance.
Objective and research questions
The main objective of the present study is to further in-
vestigate combined treatment approaches for MDD by
evaluating an empirically validated web-based treatment
(deprexis; [23-25]) as an adjunctive tool in regular psy-
chotherapeutic treatment in comparison with traditional
psychotherapy in a sample of depressed outpatients by
means of a pragmatic RCT in routine care. Therefore,
our main hypothesis is that the combined treatment (TAU
plus Deprexis) is more effective than regular psychothera-
peutic treatment (TAU) alone.
Additionally, during a 6-month period we intend to test
on an exploratory basis how helpful patients as well as
therapists rate the combined treatment and whether the
combination is associated with increased efficiency (i.e.,
reduction of number of sessions) or with negative side




A two-armed randomized pragmatic RCT is currently
being conducted to compare regular face-to-face psy-
chotherapeutic treatment with a combined treatment,
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based adjunctive treatment tool (deprexis). Measurements
in both conditions are assessed at baseline (T0), after six
weeks (process measures), after three months (T1), and
after six months follow-up (after randomization) (T2).
The study design is shown in Figure 1.Ethics
The study is being conducted in compliance with the
Declaration of Helsinki and has been approved by the
Ethics Committee of the German Psychological Associ-
ation (DGPs, TB072013; 16/08/2013) and the Hamburg
Chamber of Psychotherapists (18/12/2013). Participants
are informed that they can withdraw at any time without
having to disclose reasons. Informed consent is obtained
online prior to the baseline assessment. All participants






Regular psychotherapy plus Deprexis
N=400 
Assessment T1 
3 months after randomization 
Assessment T2 
6 months after randomization 
Figure 1 Study design.about the aim of the study, benefits and risks of partici-
pation and the study procedure.
Inclusion and exclusion criteria
We include adults (a) with age 18 and above, who (b)
suffer from a MDD according to the International
Classification of Diseases (ICD-10; i.e., F32.-depressive
episode, F33.- Recurrent Depressive Disorder, F34.- Per-
sistent Affective Disorder, F38.- Other Affective Disorder,
F39 Unspecified Affective Disorder), (c) have a Beck
Depression Inventory (BDI-II) sum score over 13, (d) have
sufficient knowledge of the German language, (e) have
Internet access and sufficient knowledge to use it (based
on self-report), and (f) are willing to give informed con-
sent. All participants are recruited in Germany.
We will exclude subjects who (a) have a known psych-
otic or bipolar disorder, (b) suffer from a chronic depres-
sion with onset in childhood (based on clinical judgment),tients with a 
 initial treatment 
=1000) 
Exclusion (N=200) 
BDI-II  13 
Suicidal tendencies 
Age < 18 
Exclusion diagnoses 







3 months after randomization 
Assessment T2 
6 months after randomization 
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judgment of the therapists).
Recruitment
Forty therapists, all members of the Deutsche Psychother-
apeutenVereinigung (DPtV), working in secondary care
will be recruited. All therapists are informed about the
study by the DPtV and all interested members are invited
to participate in the study. Participating therapists inform
their self-referred patients about the study and ask them if
there are willing to take part in the present study. Poten-
tial study participants (patients) are informed about the
possibility of taking part in the present study in the initial
therapy session by their therapist. Interested patients re-
ceive an information sheet and a written informed consent
form by the therapists and are invited to ask questions.
After returning the completed informed consent form in-
dividually to the therapists, participants are asked to
complete online screening questionnaires at home to as-
sess whether they fulfill the inclusion criterion of BDI-II-
Score > 13.
Randomization
Participants who return the informed consent and meet
all of the inclusion and none of the exclusion criteria
will be randomly allocated to the study conditions
(50:50). Randomization takes place at an individual level
within therapists. Thus, therapists provide both treat-
ments, allowing us to control for therapist effects. The
allocation list will be produced using an automated
computer-generated random numbers table placed in a
secured web-based database and will be concealed to
the investigators and the therapists (www.random.org).
After randomization, the participant and his or her ther-
apist will be informed about the condition by email.
Blinding
In the present study, there is no blinding implemented,
consistent with recommendations for the conduct of
pragmatic RCTs [26]. All participants will be informed
about the aims and the methodology of the study. They
can ask questions regarding the study and withdraw their
informed consent at any time. The focus of the present
study is on external validity and generalizability of the re-
sults to routine clinical practice.
Description of the interventions
Intervention group: Psychotherapy plus web-based online
platform (deprexis)
Participants in the intervention group receive access to
the deprexis platform. Trained, certified psychotherapists
introduce the patients to the use of the program. There
are no costs for patients or therapists for the program
use during the study.Deprexis provides psychoeducational information and
exercises that are mainly based on cognitive-behavioral
psychotherapy and aim at decreasing depressive symp-
toms. Deprexis includes ten modules plus one summary
module: (1) psychoeducation, (2) behavioral activation, (3)
cognitive restructuring, (4) mindfulness and acceptance,
(5) interpersonal skills, (6) relaxation, (7) physical activity
and lifestyle modification (e.g., exercise and nutrition), (8)
problem-focused approaches, (9) expressive writing and
schema-focused contents, (10) positive psychology as well
as emotion-focused-interventions. A more comprehensive
description of the program can be found in Meyer and
colleagues [23].
Communication between the participant and deprexis
takes place over simulated online-dialogues in which the
user reacts to the content by clicking on multiple-choice
answers, e.g., in order to express doubts, to confirm par-
ticular contents, or to request further information. Text
units are illustrated with drawings, pictures and audio
clips. The modules can be accessed repeatedly during the
intervention interval. Depending on the reading speed of
the participants the completion of a module takes between
10 and 60 minutes.
Furthermore, deprexis includes short questionnaires
for the assessment of current mood, which offers the
possibility to visually inspect the mood trajectory over
the course of therapy. Additionally, the program pro-
vides the user with printable summaries and work
sheets. Optionally, the user receives daily short text
messages to remind him or her to use the program and
reiterate program content.
Therapists can support participants with the program
use following clinical judgment and discuss progress
with them during face-to-face sessions. For this purpose,
therapists will be introduced to the content of the
program and the “therapist cockpit” in a three-hour
workshop. In the therapist cockpit, therapists can track
participants’ program use and symptomatic progress. In
the workshops, therapists are informed that the pro-
gram can be regarded as an adjunctive tool that need
not influence the content of their face-to-face sessions.
For continuous support, participating therapists can con-
tact the program developer and owner (GAIA AG,
Hamburg) by phone or email as required.Control group: Psychotherapy without Deprexis
Patients in the control group receive regular psychother-
apy, i.e., usually weekly one-hour sessions, according to
the clinical judgment of the therapists. The behavior of
the therapists and the number of therapy sessions are
not deliberately influenced by the study. In case of inter-
est, participants in the control condition will receive ac-
cess to deprexis after completion of the study.
Krieger et al. BMC Psychiatry 2014, 14:285 Page 5 of 8
http://www.biomedcentral.com/1471-244X/14/285Therapists
All therapists are members of the DPtV. With over
10,000 psychotherapists the DPtV is the largest advocacy
for approved psychological psychotherapists and child
and adolescent psychotherapists in Germany. Most par-
ticipating psychotherapists in the study identify themselves
as being eclectic with a focus on cognitive-behavioral ther-
apy, but also psycho-dynamically oriented therapists take
part in the study.Sample size calculation
Regarding differences between the two active treatment
conditions, we want to be able to detect standardized
between-groups effects sizes (Cohen’s d) of 0.2. Smaller
effect sizes are considered to be negligible from a clinical
point of view [27]. At an α error level of .05 (two-tailed),
a statistical power (1-Beta) of .80, and a correlation be-
tween pre- and post-measurements found in our earlier
studies, we need to include 800 participants. This sample
size calculation is conservative and is based on a current
meta-analysis in which a mean effect of d = .28 for online
depression programs was found [5]. Since in the current
study participants in both conditions will receive psycho-
therapy, a significant reduction of depressive symptoms
can also be expected in the control condition. Therefore, a
relatively small effect size between conditions, i.e., depres-
sion level after three months between deprexis plus psy-
chotherapy vs. psychotherapy is expected.Table 1 Outcome measures
Patients
T0 (Baseline) • Demographic Variables Questionna
• Depression: BDI-II
• Suicidal tendencies: SBQ-R
• Web Screening Questionnaire (WSQ
• Anxiety: GAD-7
• Somatic symptoms: PHQ-15
• Health-related quality of life: SF-12
• Questionnaire for the evaluation of
courses (FEP-2)
• Empowerment: Psychological Empo
6 weeks Working Alliance Inventory (patient -
12 weeks Working Alliance Inventory (patient -
T1 (Primary endpoint) 3 months As baseline, plus:
• Subjective rating of the treatment c
In intervention group: Subjective ra
T2 (Secondary endpoint) 6 months As Baseline, plus:
• Subjective rating of the treatment c
In intervention group: Subjective raPrimary and secondary outcomes
Primary outcome is depressive symptoms assessed with
the Beck Depression Inventory, second edition (BDI-II). In
secondary analyses, we will explore the effects on quality of
life, anxiety, somatic symptomatology, health-related qual-
ity of life, psychological aspects of the treatment process,
and psychological empowerment. All measurements are
assessed online. In order to promote completion when as-
sessments are missing, participants will be automatically
reminded twice to complete the assessments. For an over-
view of all outcome measures, see Table 1.
Outcome measures
Depressive symptomatology
The German version of the BDI-II [28] will be the pri-
mary outcome measure. The BDI-II is a widely used
self-report measure for the assessment of depression se-
verity with good psychometric properties and a comple-
tion time of 5-10 minutes. Analogous to a previous
study [25] on the efficacy of online depression treatment,
we only include patients with a score greater than 13.
Scores from 0-13 indicate no or minimal depressive
symptoms, scores from 14-19 indicate mild depression,
from 20-28 moderate depression, and from 29-63 severe
depression.
Web Screening Questionnaire (WSQ)
The WSQ is a 15-item self-report instrument screening
for frequent mental disorders [29]. Evidence indicatingTherapists
ire • Questions regarding the theoretical orientation
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phobia, panic disorder with agoraphobia, agoraphobia
without panic disorder, obsessive-compulsive disorder and
alcohol abuse/dependence (sensitivity .72-1.00; specificity
.63-.80) [29]. Somewhat more modest psychometric prop-
erties have been reported for major depressive disorder,
generalized anxiety disorder, posttraumatic stress disorder,
specific phobia and panic disorder without agoraphobia
(sensitivity: .80-.93; specificity: .44-.51) [29].
Suicidal tendencies
Current suicidal tendencies will be assessed by means of
the Suicidal Behaviours Questionnaire-Revised (SBQ-R)
[30]. This self-report measure consists of four questions
regarding lifetime suicidal tendencies, the frequency of
suicidal thoughts during the last 12 months, the course
of suicidal intentions, and the probability of suicidal be-
havior in the future. The SBQ-R has shown high internal
consistency. Furthermore, it has shown clinical utility in
that scores on the instrument differentiated between sub-
groups of suicidal and nonsuicidal youth and adults [30].
Anxiety
Symptoms of anxiety are assessed with the German ver-
sion of the 7-item Generalized Anxiety Disorder Scale
[31] in order to identify patients with a generalized anxiety
disorder and to assess anxiety symptoms. The GAD-7
consists of seven items that correspond to the diagnostic
criteria for GAD from the DSM-IV. The GAD-7 has good
internal consistency and good convergent validity with
other anxiety scales [32].
Somatic symptomatology
To assess the level of somatic symptoms, patients complete
the somatic symptom module of the Patient Health Ques-
tionnaire (PHQ), the PHQ-15 [33]. The items include the
most prevalent somatic symptom complaints reported in
primary care. Each symptom is scored from 0 (“not both-
ered at all”) to 2 (“bothered a lot”). The PHQ-15 has shown
to be equal or superior to other brief measures for asses-
sing somatic symptoms and screening for somatoform
disorders [32].
Quality of life
To assess quality of life, patients complete the Short-Form
Health Survey-12 (SF-12). The SF-12 is based upon the
Short-Form Health Survey (SF-36). Its two subscales
measure physical and mental aspects of health-related
quality of life. It captures general health as well as pain,
disabilities in daily life and mental problems. The SF-12
asks for the presence and severity of 12 items over the
course of the last four weeks. The re-test reliability is good
and it is roughly equivalent to the long form [34].Psychological aspects of the treatment process
The Questionnaire for the evaluation of psychothera-
peutic progress (FEP-2) is a measure of therapeutic pro-
gress and can be used for both change and outcome
assessment [35]. Forty items measure the dimensions
well-being, symptoms, interpersonal relationships, and
incongruence with respect to approach and avoidance
goals. The instrument has shown to be change sensitive
as well as reliable and it is available in the public domain.
It represents the phase model of therapeutic change as
well as interpersonal and integrative models of psycho-
therapy [36].
Psychological empowerment scale
Empowerment is a psychological motivational construct,
which includes for domains: competence, meaning, self-
determination, and impact. Psychological empowerment
will be assessed with an adapted version of the scale by
Spreitzer [37,38].
Process measure
After six and 12 weeks the cooperation between the patient
and the therapist will be assessed with the German version
of the Working Alliance Inventory – Short (WAI-S;
adapted version) [39]. The WAI-short (WAI-S) is a 12-
item self-report measure of Working Alliance. Each item is
rated on a 7-point scale, with higher scores indicating
higher alliance. The WAI-S is scored into three subscales
measuring Task, Goal and Bond. The Task and Goal scales
are intended to measure agreement between the client and
therapist with regard to Tasks and Goals of the treatment.
The Bond subscale aims to measure the empathic bond be-
tween the client and the therapist [40].
Other measurements
Patients are self-reporting a number of demographic
variables including sex, marital status, level of education.
Additionally, we assess the patients’ medication status.
Therapist measurements
We collect information from the therapists such as the
diagnoses based on clinical judgment, number of therapy
sessions, and self-reported usefulness and implementation
of deprexis in mental care. Therapists’ variables such as
age, gender, self-identified theoretical orientation, and
years of experience are collected from therapists through
a questionnaire.
Statistical analyses
Primary and secondary outcomes will be conducted on
the intention-to-treat (ITT) sample. A linear mixed-model
repeated measures ANOVA with time as a within groups
factor and treatment condition as a between-groups factor
will be used for the main research question. Mixed-model
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subject and does not involve the substitution of missing
values [41]. With regard to the process variable, i.e., the
quality of the working alliance, we will conduct Pearson
correlations of the WAI with residualized change scores
on the primary and secondary outcomes.
Discussion
Major depression is a prevalent and debilitating disorder.
Even though there is ample evidence for the efficiency
and effectiveness of (guided) Internet-based interven-
tions as well as for conventional psychotherapeutic treat-
ments for depression, there are various strengths and
limitations for both forms of treatments [11].
In this study, we will examine the effectiveness of psy-
chotherapy plus a web-based online depression program
(deprexis) versus traditional psychotherapy in routine
care. We expect that depression levels of participants in
the intervention group will be significantly lower after
three months and after six months compared to the
control group. Additionally, we will gain valuable experi-
ences in combining an online psychological intervention
with routine psychotherapeutic care.
A major strength of this study is that to the best of our
knowledge, it will be the first study that tests whether an
adjunctive web-based treatment tool in psychotherapy for
depression can be successfully integrated in routine care
and whether the combination will show additional effects
compared to a regular psychotherapy for depression.
There are important limitations in the present study
that should be mentioned: First, we adopted a crossed
therapist design, i.e., a given therapist delivers the con-
trol as well as the experimental condition. This design is
associated with potential drawbacks [42] but was neces-
sary to choose in order to be able to run the study in
routine care. In order to adjust for the potential down-
sides of this design, in the analyses we will control for
therapist allegiance. Second, we will not have standard-
ized assessments of depression diagnosis but rely solely
on clinical diagnoses of experienced, licensed psychothera-
pists plus an online self-report diagnostic assessment.
Third, in the present study, we will use deprexis as the
only adjunctive web-based intervention tool. Therefore,
generalizability of the results to other web-based interven-
tions will be restricted.
In addition to the main analysis described in the
methods section, our study will be able to address a
number of other important research questions, some of
which have not been addressed before. For example, we
will be able to assess whether an adjunctive web-based
treatment affects working alliance scores. Furthermore,
we will assess attitudes towards blended psychological
interventions from the patients’ as well as the therapists’
perspective.If leading to a larger improvement, using effective
web-based programs such as deprexis as an adjunctive
treatment tool could be an interesting option to consider
in future mental health care. Additionally, this study will
also give first impressions whether blending face-to-face
psychotherapy with a web-based adjunct will have nega-
tive side effects, i.e., symptom deterioration or decrease
of the patient rated quality of the therapeutic alliance. In
general, results of this study will provide an informative
basis whether a combination of traditional face-to-face
psychotherapy and web-based depression program is feas-
ible and whether it is more effective compared to regular
psychotherapeutic treatment in depressed outpatients in
routine care.
Trial status
Currently recruiting (Ncurrent = 28 as of 800).
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